Hepatectomy Clinical Trial
— SPREDOfficial title:
Development and Validation of a Predictive Score for Surgical Site Infections (SSI): a Prospective Preoperative Trial in Major Digestive Surgery
More than 8 millions surgical interventions are carried out each year in France. Postoperative complications, in particular infectious, can occur in 10 to 60% of cases and are the cause of postoperative revision in 30% of cases, an increase in mortality, length of stay, readmissions and lead to significant additional socio-economic costs. Currently, improvements in surgical practices have not reduced the incidence of surgical site complications. In this context, the development of predictive scores for the risk of post-operative complication becomes urgent in order to implement new interventions (pre-habilitation) or to modify surgical decisions (timing, approach) in order to reduce the risk of complications before surgery. Several recent studies highlights the importance of the immune response in postoperative prognosis. In particular, an imbalance between the adaptive and innate response involving MDSCs has been demonstrated in patients with postoperative complications.Thanks to new techniques for analyzing the immune system, in-depth analysis of the immune system before surgery is a very promising approach aimed at identifying predictive biomarkers of postoperative prognosis. Our team has developed and patented a multivariate model integrating mass cytometry data, proteomics and clinical data collected before surgery to accurately predict the occurrence of a surgical site complication (AUC = 0.94, p<10e-7) in a monocentric cohort of 43 patients to major abdominal surgery (Stanford University). The objective of the present study is to generalize and validate this preoperative predictive score of infectious complications of the surgical site in the 30 days following major digestive surgery on a larger workforce within a multicenter cohort and to validate this score at using a machine learning method.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | December 1, 2023 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: Patients will be included: - Aged 18 and over - Having undergone elective major digestive surgery: Major surgery defined according to the recent recommendations of the European Surgical Association - PMID: 32172309 by a rate of infectious or cognitive complications between 20 and 30% according to the ACS risk calculator - Having expressed their non-opposition to participate in the study - Being affiliated to a French health insurance Exclusion Criteria: Patients with the following criteria will not be included: - Aged under 18 - Having an ASA 4 or more, in palliative care - Having an expected duration of hospitalization < 24 hours - Not speaking French, illiterate patient - Having expressed their opposition to participate in the study - Current pregnancy or breastfeeding - Absence of affiliation to social security plan - Being deprived of liberty or under guardianship |
Country | Name | City | State |
---|---|---|---|
France | La pitiè Salpâtrière Hospital | Paris | |
France | Saint Antoine Hospital | Paris | |
France | Saint Joseph Hospital | Paris | |
France | FOCH Hospital | Suresnes |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch | surge2surgery |
France,
Gaudilliere B, Angst MS, Hotchkiss RS. Deep Immune Profiling in Trauma and Sepsis: Flow Is the Way to Go! Crit Care Med. 2017 Sep;45(9):1577-1578. doi: 10.1097/CCM.0000000000002594. — View Citation
Gaudillière B, Fragiadakis GK, Bruggner RV, Nicolau M, Finck R, Tingle M, Silva J, Ganio EA, Yeh CG, Maloney WJ, Huddleston JI, Goodman SB, Davis MM, Bendall SC, Fantl WJ, Angst MS, Nolan GP. Clinical recovery from surgery correlates with single-cell immune signatures. Sci Transl Med. 2014 Sep 24;6(255):255ra131. doi: 10.1126/scitranslmed.3009701. — View Citation
Hawn MT, Vick CC, Richman J, Holman W, Deierhoi RJ, Graham LA, Henderson WG, Itani KM. Surgical site infection prevention: time to move beyond the surgical care improvement program. Ann Surg. 2011 Sep;254(3):494-9; discussion 499-501. doi: 10.1097/SLA.0b013e31822c6929. — View Citation
Storesund A, Haugen AS, Hjortås M, Nortvedt MW, Flaatten H, Eide GE, Boermeester MA, Sevdalis N, Søfteland E. Accuracy of surgical complication rate estimation using ICD-10 codes. Br J Surg. 2019 Feb;106(3):236-244. doi: 10.1002/bjs.10985. Epub 2018 Sep 18. — View Citation
Zhu X, Herrera G, Ochoa JB. Immunosupression and infection after major surgery: a nutritional deficiency. Crit Care Clin. 2010 Jul;26(3):491-500, ix. doi: 10.1016/j.ccc.2010.04.004. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Preoperative Prediction Score Performance of Surgical Site Infectious Complications | Primary Endpoint:
Preoperative Prediction Score Performance of Surgical Site Infectious Complications Defined as Superficial, Deep and Organ Surgical Site Infection as per CDC 2021 definition within 30 days post-operatively. The performance of the score will be evaluate based on the evaluation of the F1 score criterion and the AUROC. F1: score ranges from 0 to 1, where 0 is the worst and 1 is the best possible score. AUROC: score ranges from 0.5 to 1 where 1 is the best score and 0.5 means the model is as good as random. |
30 days | |
Secondary | Performance of Preoperative Lung Infection Prediction Score | defined by prescribing antibiotics with one or more of the following: sputum sputumnew or changed, new or changed lung opacities on chest x-ray, fever > 38°C, leukocytes >12 × 109 /L within 30 postoperative days.
The performance of the score will be evaluate based on the evaluation of the F1 score criterion and the AUROC. F1: score ranges from 0 to 1, where 0 is the worst and 1 is the best possible score. AUROC: score ranges from 0.5 to 1 where 1 is the best score and 0.5 means the model is as good as random. |
30 days | |
Secondary | Performance of the preoperative prediction score for urinary tract infections | Performance of the preoperative prediction score for urinary tract infections (according to the definition of the CDC - 2021) within 30 days post-operative.
The performance of the score will be evaluate based on the evaluation of the F1 score criterion and the AUROC. F1: score ranges from 0 to 1, where 0 is the worst and 1 is the best possible score. AUROC: The score ranges from 0.5 to 1 where 1 is the best score and 0.5 means the model is as good as random. |
30 days | |
Secondary | Performance of the post-operative prediction score (D1) of infectious surgical site complications | Performance of the post-operative prediction score (D1) of infectious surgical site complications defined as superficial, deep and organ infection of the surgical site according to the CDC 2021 definition within within 30 days post-operative.
The performance of the score will be evaluate based on the evaluation of the F1 score criterion and the AUROC. F1: score ranges from 0 to 1, where 0 is the worst and 1 is the best possible score. AUROC: Score ranges from 0.5 to 1 where 1 is the best score and 0.5 means the model is as good as random. |
30 days | |
Secondary | Intra-hospital mortality assessed from patient medical records | It will be assessed from patient medical records | 30 days | |
Secondary | Length of hospital stay | It will be assessed from patient medical records | 30 days | |
Secondary | Cost of stay (GHS) | Data ( GHS, GHM, cost) will be collected upon the discharge of the patient from the hospital via the medical information departments (DIM) based on the PMSI of each establishment. | 30 days | |
Secondary | The score results | The score is calculated using a machine learning method integrating immune, plasma protein and clinical data. The aim is to validate and generalize the score result (AUC = 0,94, p<10e-7) of a multivariate model already developed in a monocentric cohort of 43 patients undergoing major abdominal surgery (Stanford University). | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03651154 -
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
|
N/A | |
Completed |
NCT02041871 -
Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer
|
N/A | |
Recruiting |
NCT06044909 -
Multimodal Image Registration for Helping Laparoscopic Liver Surgery Guidance
|
||
Recruiting |
NCT03715517 -
Spinal Anesthesia For Enhanced Recovery After Liver Surgery
|
N/A | |
Recruiting |
NCT06130436 -
Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy
|
N/A | |
Recruiting |
NCT04559269 -
Microsleep 1, Micro-sleep During Maintenance Wakefulness Tests
|
||
Recruiting |
NCT04218253 -
Clinical Application of Nutrition Support Package Before Hepatectomy
|
N/A | |
Completed |
NCT03611426 -
Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy
|
Phase 1/Phase 2 | |
Completed |
NCT02817321 -
Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision
|
N/A | |
Recruiting |
NCT05598060 -
Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study
|
N/A | |
Completed |
NCT03793933 -
ACS-NSQIP Calculator for Liver Surgery
|
||
Recruiting |
NCT03540537 -
A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy
|
N/A | |
Recruiting |
NCT06166186 -
Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy
|
N/A | |
Not yet recruiting |
NCT02758977 -
Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)
|
N/A | |
Completed |
NCT01469442 -
Postoperative Biliary Fistula Prevention After Hepatectomy
|
N/A | |
Completed |
NCT00730743 -
Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection
|
N/A | |
Recruiting |
NCT02198625 -
Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication
|
Phase 4 | |
Completed |
NCT01194843 -
Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations
|
N/A | |
Completed |
NCT00200148 -
Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy
|
Phase 3 | |
Recruiting |
NCT03323359 -
Efficacy and Tolerability of Hemopatch After Hepatic Resection
|
N/A |